Furthermore, ISA is a mild/moderate CYP3A4 inhibitor with fewer drug interactions compared with posaconazole and voriconazole (39), which is safer for leukemia patients who may require targeted drugs such as venetoclax. The gene discussed is CYP3A4; the disease is leukemia.